Last update Sept. 4, 2022

Dolasetron Mesylate

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Dolasetron is an antinauseant and antiemetic, 5-HT3 antagonist, used in chemotherapy and postoperatively. Oral or intravenous administration.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data (moderately high molecular weight and wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.

Although some author considers it probably compatible (Mahadevan 2006), until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Pistilli 2013), especially during the neonatal period and in the event of prematurity.

Alternatives

  • Domperidone ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoclopramide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ondansetron ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Dolasetron Mesylate in other languages or writings:

Groups

Dolasetron Mesylate belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Dolasetron Mesylate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 75 %
Molecular weight 421 daltons
Protein Binding 69 - 77 %
VD 5.8 l/Kg
pKa 12.18 -
Tmax 1 hours
8.1 hours

References

  1. Pistilli B, Bellettini G, Giovannetti E, Codacci-Pisanelli G, Azim HA Jr, Benedetti G, Sarno MA, Peccatori FA. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013 May;39(3):207-11. Abstract
  2. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)

Total visits

4,118

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM